The disclosure relates to heteroarylamide derivatives having formulae (Ia), (Ib) or (Ic) and N-oxides, stereoisomers and pharmaceutically acceptable salts thereof, wherein the variables are as defined in the specification. These arylamide derivatives have antiandrogenic properties and are suitable for treating androgen receptor related disorders selected from the group consisting of prostate cancer, castration-resistant prostate cancer and prostate hyperplasia. The disclosure also relates to the use of these arylamide compounds as a medicament and to pharmaceutical compositions comprising them and to their preparation.
